期刊文献+

基于共病性原则筛选PCOS潜在治疗药靶 被引量:2

Based on co-morbility principle to screening PCOS ' potential therapeutic targets
下载PDF
导出
摘要 目的寻找多囊卵巢综合征的潜在治疗药靶。方法采用Grapweb软件中的MCL clustering算法,在蛋白质互作网络中,分别以2型糖尿病和多囊卵巢综合征的已知致病基因为种子,挖掘两种疾病共病性模块;以DAVID功能富集分析软件进行模块中基因的GO功能注释和通路富集显著性分析(FDR<0.05)。结果获得了68个共病性模块,其中2个为多囊卵巢综合征的潜在药靶模块。结论得到PPARG、ESR1与ESR2等潜在治疗药物靶点。 Objective To look for potential targets of polycystic ovary syndrome. Methods In the protein-protein interaction network,known disease genes of type 2 diabetes and polycystic ovary syndrome as seeds to mine diseases related modules by MCL clustering in grapweb; In DAVID,gene-annotation enrichment analysis,functional annotation clustering and Bio Carta KEGG pathway mapping for module's disease-related genes were formation by using hypergeometric distribution method( FDR〈0. 05). Results Sixty-eight co-morbility modules were got,in which two pairs of modules contained type 2 polycystic ovary syndromes' targets. Conclusion PPARG,ESR1,ESR2 and potential drugs are obtained potential targets.
出处 《哈尔滨医科大学学报》 CAS 2016年第3期189-191,共3页 Journal of Harbin Medical University
基金 国家自然科学基金资助项目(61272388) 国家及黑龙江省大学生创新创业训练基金(201410226010) 黑龙江省卫生厅科研课题(2012-810) 黑龙江省教育厅课题(112541476)
关键词 多囊卵巢综合征 2型糖尿病 共病性 模块 polycystic ovary syndrome type 2 diabetes co-morbility module
  • 相关文献

参考文献9

  • 1Salilew-Wondim D, Wang Q, Tesfaye D, et ol, Polycystic ovarian syndrome is accompanied by repression of gene signatures associat?ed with biosynthesis and metabolism of steroids, cholesterol and lipids[J].J Ovarian Res, 2015,8 :24.
  • 2LordJM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis[J]. BMJ, 2003, 327(7421) :951-953.
  • 3Barber TM, Franks S. The link between polycystic ovary syndrome and both Type 1 and Type 2 diabetes mellitus: what do we know today?[J]. Womens Health (Lond Engl) , 2012,8 (2) :147- 154.
  • 4Li X, Shao R. PCOS and obesity: insulin resistance might be a common etiology for the development of type I endometrial carcino?marJ]. AmJ Cancer Res, 2014,4(1) :73-79.
  • 5Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials[J].JAMA, 2007, 298 ( 10) : 1180-1188.
  • 6Benardeau A, BenzJ, Binggeli A, et al, Aleglitazar, a new, po?tent, and balanced dual PPAR alpha/gamma agonist for the treat?ment of type II diabetes[J]. Bioorg Med Chern Lett, 2009, 19 (9) :2468-2473.
  • 7Yanase T, Tanabe M, Nomiyama T. Sex hormones and metabolic function[J]. Nihon Rinsho, 2015,73(4) :571-575.
  • 8Hagag P, Steinschneider M, Weiss M. Role of the combination spironolactone-norgestimate- estrogen in Hirsute women with poly?cystic ovary syndrome[J].J Reprod Med, 2014,59(9-10) :455- 463.
  • 9Rae M, Grace C, Hogg K, et al. The pancreas is altered by in utero androgen exposure: implications for clinical conditions such as polycystic ovary syndrome (PCOS)[J]. PLoS One, 2013,8 (2) :e56263.

同被引文献31

引证文献2

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部